



HOLTORF MEDICAL GROUP, INC.

CENTER FOR HORMONE IMBALANCE, HYPOTHYROIDISM AND FATIGUE

23456 Hawthorne Blvd. Suite 160, Torrance, CA 90505 Tel: 310-375-2705 Fax: 310-375-2701

OBESITY HAS BECOME A MAJOR health epidemic and has dramatically increased over the last decades. Studies show that now approximately one-third of the U.S. population is classified as obese and over two-thirds are significantly overweight. While the cause is multifactorial, studies are clear that almost all overweight individuals have metabolic and endocrinological dysfunction that is causing or contributing to their inability to lose weight. It is not simply a problem that individuals are taking in more calories than they are consuming, but rather it is a complex vicious-cycle of endocrinological and metabolic dysfunction. Contemporary medicine has failed to address these dysfunctions in overweight individuals and doctors and patients continue to believe that all cases are a matter of will-power and lifestyle. Thus, it is no surprise that obesity is reaching epidemic proportions.

Leptin

The hormone leptin has been found to be a major regulator of body weight and metabolism and dysfunctional leptin signaling results in one of many viscous-cycles that prevent individuals from losing weight. Leptin is secreted by fat cells and the levels increase with the accumulation of fat. The leptin should then feed-back to the hypothalamus as a signal that there are adequate energy (fat) stores, and this should signal the body to burn fat rather than continue to store excess energy.

Studies are finding, however, that the majority of overweight individuals that are having difficulty losing weight have varying degrees of leptin resistance. The leptin is unable to produce its normal effects of weight loss, with the severity correlating with the degree of obesity (1-5). This leptin resistance results in a leptin deficiency in the hypothalamus, which is sensed as starvation, so multiple mechanisms are activated to increase fat stores, as the body perceives a state of starvation (1-30). Baseline leptin levels and the degree of leptin resistance is

shown to be a good predictor of a person's likelihood of achieving successful weight loss with dieting (68-70).

The metabolic effects of leptin resistance include a diminished TSH secretion, a suppressed T4 to T3 conversion, an increase in reverse T3, an increase in appetite, an increase in insulin resistance and an inhibition of lipolysis (fat breakdown) (1-29,31). These effects of leptin resistance on thyroid hormones contribute to the drop in TSH and T3 levels that occur with dieting and results in decreased tissue thyroid action and a depressed metabolic rate that inhibits weight loss and promotes weight gain (1,6,10,14,18-23,29,30-37). Unfortunately, standard thyroid function tests miss over 80% of this type of hypothyroidism, as the TSH, free T4 and free T3 levels are typically in the normal range (1,6,10,14,31,38-46). In primary hypothyroidism, diminished thyroid hormones stimulate the hypothalamus to increase TRH secretion, which in-turn stimulates the pituitary to secrete TSH. Thus, the TSH serves as the basis for the diagnosis of primary hypothyroidism, but with the suppression of TSH that occurs with leptin resistance, this feed-back is interrupted and a normal TSH level cannot be used to rule out a significant thyroid deficiency (1,6,10,14,31,38-46).

Starvation dieting can decrease resting metabolic rate by as much as 40% and food restriction at a level to maintain just a 10% reduction in body weight results in significantly decreased intracellular thyroid hormone levels and a diminished metabolic rate that does not return to normal even after a normal diet is resumed (10,18-23,29,30,32,33-37). When combined with the effect of leptin resistance, this accounts for the majority of regained weight in weight reduced subjects (17-22,25,26,31,35,36,47). Low intracellular leptin levels are inversely correlated with reverse T3 (rT3), which may currently be the best marker, along with the T3/rT3 ratio, for diminished T4 to T3 conversion and cellular hypothyroid-

Endocrinological Assessment and Treatment of Weight Gain & Obesity.

ism in chronic illness (18,48-59). Reverse T3 has been thought to be an inactive metabolite, but it has been shown to be a competitive inhibitor of T3 (blocks T3 activity), directly decreasing cellular energy production, and to directly suppresses T4 to T3 conversion (47,56-59). In fact it is shown to be a more potent inhibitor of T4 to T3 conversion than PTU (56), a medication used to decrease thyroid hormone levels in hyperthyroidism.

In addition, increased adipose tissue results in a maladaptive stimulation of inflammatory cytokines, including TNF-alpha, IL-6 and CRP, which further suppress TSH secretion and the conversion of T4 into T3, as well as increasing the conversion of T3 into rT3 (60-64).

Diagnosis:

If individuals are having difficulty losing weight, we recommend obtaining a metabolic panel that consists of a leptin level, TSH, free T4, free T3, reverse T3, TPO antibody, antithyroglobulin antibody, glucose, insulin, HgA1c, IGF-1, testosterone, CRP, TNF-alpha (highly sensitive), IL-6 (highly sensitive), CRP, homocystine, SHBG and lipids. In addition, the relaxation phase of the ankle or brachioradialis muscle can be measured. This has been shown to correlate with the degree of hypothyroidism and to be a better indicator of tissue levels of thyroid than standard thyroid function tests (50,65,66).

While a complete review of the interpretation of these labs is beyond the scope of this article, as it not as simple as looking at what is normal or abnormal and ratios typically need to be evaluated. In general, however, a leptin level greater than 10 is associated with leptin resistance. Thus, if the leptin level is above 10, the TSH is unreliable (artificially decreased) and a normal TSH cannot be used to rule-out significant cellular hypothyroidism. Likewise, if the inflammatory markers CRP, TNF-alpha or IL-6 are relatively (high normal) or overtly elevated,

(over)

which is often the case with numerous conditions including insulin resistance, diabetes, obesity, lupus, rheumatoid arthritis, stress, sleep apnea, depression, chronic fatigue syndrome, fibromyalgia, heart disease and insomnia, the TSH is not a reliable indicator of tissue levels of active thyroid hormone. The T3/rT3 ratio is typically the best marker for tissue hypothyroidism in these conditions, as again, the TSH is not reliable if leptin resistance or inflammation is present. Insulin levels along with the HgA1c, glucose and lipids are used to evaluate insulin resistance, another reason for problems with weight gain. A muscle reflex relaxation phase of greater than 110 msec also demonstrates low tissue levels of thyroid.

Treatment:

There are new medications, Byetta and Symlin, that decrease leptin resistance. These can be very beneficial treatments and can produce dramatic weight loss if given in conjunction with other metabolic treatments. While these medications are approved for type II diabetes and are showing significant weight loss in this patient population, they are showing promise in the non-diabetic population as well. The amount of weight loss varies according to the study design, but a significant percent of patients are having dramatic weight loss, despite little or no change in diet. Again, this demonstrates that many overweight patients have a metabolic problem rather than a problem of will-power. While these medications, by themselves, typically result in modest weight loss, combining these medications with metabolic treatments and a healthy lifestyle can allow for significant sustained weight loss.

A thorough analysis and work up will find that many overweight patients have, in addition to leptin resistance, dysfunction of the hypothalamus-pituitary-thyroid axis as well as dysfunction of the peripheral (cellular) thyroid metabolism and utilization. Correction of these dysfunctions can result in dramatic long term successful weight loss. If high reverse T3 is found, T4 preparations such as Synthroid or Levoxyl are shown to be ineffective in restoring tissue thyroid levels (67). T4/T3 preparations such as Armour thyroid are better but timed re-

leased T3 preparations are the most effective at restoring tissue T3 levels and often effective when Armour thyroid, Synthroid and Levoxyl fail to restore normal tissue levels of thyroid.

References

- Dagogo-Jack S. Human Leptin Regulation and Promis in Pharmacotherapy. *Current Drug Targets* 2001;2:181-195.
- Andersson RV, Sinha MK, Heiman ML, Kraicunas A, Stephens TW, Nyce MR, Oshannian JP, Marco CC, Mckee LJ, Bauer TC, Caro JF. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *New England Journal of Medicine* 1996;334:292-295.
- Dagogo-Jack S, Tanellis C, Paramore D, Brother SJ, Land TM. Plasma Leptin and Insulin Relationships in Obese and Nonobese Human. *Diabetes* 1996;45:695-698.
- Maffei M et al. Leptin levels in human and rodent: measurement of plasma leptin and ob/NAN in obese and weight-reduced subjects. *Nature Medicine* 1995;1:1155-1161.
- Sandra G et al. Serum leptin in children with obesity. Relationship to gender and development. *1996;98:201-203.*
- Kozłowska L, Rosolowska-Huszcz. Leptin, Thyrotropin, and Thyroid Hormones in Obese/Overweight Women Before and After Two Levels of Energy Deficit. *Endocrine* 2004;24(2):147-153
- Fekete C et al. Differential Effects of Central Leptin, Insulin, or Glucose Administration during Fasting on the Hypothalamic-Pituitary-Thyroid Axis and Feeding-Related Neurons in the Arcuate Nucleus. *Endocrinology* 2006;147(1):520-529
- Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS 1996 Role of leptin in the neuroendocrine response to fasting. *Nature* 382:250-252
- Legradi G, Emerson CH, Ahima RS, Flier JS, Lechan RM. Leptin prevents fasting-induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid in neurons of the hypothalamic paraventricular nucleus. *Endocrinology* 1997;138:2569-2576
- Zimmermann-Belsing T et al. Circulation leptin and thyroid dysfunction. *European Journal of Endocrinology* 2003;149:257-271.
- Schwartz MW, Woods SC, Porte D, Seelye RJ, Baskin DG. Central nervous system control of food intake. *Nature* 2000;404:61-67.
- Mantzoros CS, Moschos SJ. Leptin: in search of role(s) in human physiology and pathophysiology. *Clinical Endocrinology* 1998;49:551-567.
- Frühbeck G, Jebb SA, Prentice AM. Leptin: physiology and pathophysiology. *Clinical Endocrinology* 1998;49:551-567.
- Flier JS, Harris M, Hollenbar A. Leptin, nutrition and the thyroid: the why, the wherefore and the wiring. *The Journal of Clinical Investigation* 2000;105(7):859-861.
- Gon DW, He y, Karas M, Reitman M. Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, beta 3-adrenergic agonists and leptin. *Journal of Biological Chemistry* 1997;272:24129-24132.
- Cusin I, Rouru J, Visser T, Burger AG, Rohner-Jeanrenaud F. Involvement of thyroid hormones in the effect of intracerebroventricular leptin infusion on uncoupling protein-3 expression in rat muscle. *Diabetes* 2000;49:1101-1105.
- Rosenbaum M, Godsmith R et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. *J. Clin. Invest* 2005;115:3579-3586.
- Rosenbaum M, Murrphy et al. Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulation concentration of thyroid hormones. *JCEM* 2002;87(5):2391-2394.
- Leibel RL et al. 1995. Changes in energy expenditure resulting from altered body weight. *N Eng J Med*. 332:621-28.
- Rosenbaum M et al. The effects of changes in body and thyroid function. *Amer J Clinical Nutrition* 2000;71:1421-32.
- Ahima, R et al. Role of leptin in the neuroendocrine response to fasting. *Nat*. 1996;382:250-52
- Rosenbaum M et al. 1997 Effects of weight change on plasma leptin concentrations and energy expenditure. *J Clin. Endocrinol. Metab* 1997;82:3647-54
- Legradi G et al. 1998. Leptin prevents fasting-induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid in neurons of the hypothalamic paraventricular nucleus. *Endocrinol*. 1998;138:2569-76.
- Boozer C et al. Synergy of leptin and sibutramine in treatment of diet-induced obesity in rats. *Metab*. 2001;50:889-93.
- Campfield LA et al. Recombinant mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks. *Sci* 1995;269:546-48.
- Farooqi I et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. *N Eng J Med* 1999;341:879-84.
- Chehab F. Leptin as a regulator of adipose tissue mass and reproduction. *Trends Pharmacol Sci* 2002;23:309-14.
- Rosenbaum K et al. The role of leptin in human physiology. *N Eng J Med* 1999;341:913-15.
- Naslund, E et al. 2000. Associations of leptin, insulin resistance and thyroid function with long-term weight loss in dieting reduced-obese men. *JIntMed*, 248:299-308.
- Doucette, E, et al. 2000. Appetite after weight-loss by energy restriction and a low-fat diet-exercise follow up. *Int J Obesity* 2000;24:906-14.
- Roos A, et al. Thyroid function is associated with components of the Metabolic syndrome in Euthyroid Subjects. *J Endocrinology & Metabolism* 2007;92(2):491-496.
- Leibel R.L et al. 1984. Diminished energy requirements in reduced obese patients. *Metabolism* 1984; 33:164-70.
- Lowell B, Spiegelman B. Towards a molecular understanding of adaptive thermogenesis. *Nature* 2000;404:652-660.
- Silva JE. Thyroid hormone control of thermogenesis and energy balance. *Thyroid*. 1995 Dec;5(6):481-92.
- De Boer Jo, Van Es EJ, Roovers L.C, Van Raaij JM, Hautvast JG. Adaptation of energy metabolism of overweight women to low-energy intake, studied with whole-body calo-

rimeters. *American Journal of Clinical Nutrition* 1986;44:585-595.

- Kak P, Roselfema F et al. High Circulating Thyrotropin Levels in Obese Women Are Reduced after Body Weight Loss Induced by Caloric Restriction. *Journal of Clinical Endocrinology* 2005;90(8):4659-4663.
- Weinsier RL et al. Do adaptive changes in metabolic rate favor weight regain in weight-reduced individuals? An examination of the set-point theory. *Am J Clin Nutr* 2000 Nov;72(5):1088-94.
- NeecK G, Riedel W. Thyroid Function in Patients with Fibromyalgia Syndrome. *J of Rheumatology* 1992;19:71120-1122.
- Rose SR, Lustig RH; Pitukcheewanont P, Broome DC, Burghen GA; Li H; Hudson MM; Kun LE. Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. *J Clin Endocrinol Metab* 1999 Dec;84(12):4472-9
- Lowe JC. Thyroid Status of 38 Fibromyalgia Patients: Implications for the Etiology of Fibromyalgia. *Clin Bull Myofascial Therapy*, 2(1):47-64, 1997.
- Wiersinga WM 2000 Nonthyroidal illness. In: Braverman LE, Utiger RD, eds. *The thyroid*. Philadelphia: Lippincott; 281-292
- Docter R, Krenning EP, de Jong M, Hennemann G. The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism. *Clin Endocrinol (Oxf)* 1993;39:499-518
- Wartofsky L, Burman KD 1982 Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome." *Endocr Rev* 3:164-217
- Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR 2002 Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenoenzymes. *Endocr Rev* 23:38-89
- Mclver B, Gorman CA 1997 Euthyroid sick syndrome: an overview. *Thyroid* 7:125-132
- Van den Beld AW et al. Thyroid Hormone Concentrations, Disease, Physical Function and Mortality in Elderly Men. *The Journal of Clinical Endocrinology & Metabolism* 2005; 90(12):6403-6409
- Sechman A et al. The relationship between basal metabolic rate (BMR) and concentrations of plasma thyroid hormones in fasting cokerels. *Folia Biol (Krakow)*. 1989;37(1-2):83-90.
- Corsonello A et al. Plasma leptin concentrations in relation to sick euthyroid syndrome in elderly patients with nonthyroidal illness. *Gerontol* 2000;46:64-70.
- Peeters RP, Wouters PJ, Van Toor H et al. Serum 3,3',5'-Triiodothyronine (rT3) and 3,5,3'-Triiodothyronine/rT3 Are Prognostic Markers in Critically Ill Patients and Are Associated with Postmortem Tissue Deiodinase Activities. *The Journal of Clinical Endocrinology & Metabolism* 2005;90(8):4559-4565
- Annewieke W. Van den Beld, Theo J. Visser, Richard A. Feelders, Diederick E. Grobbee, and Steven W. J. Lamberts Thyroid Hormone Concentrations, Disease, Physical Function, and Mortality in Elderly Men. *J Clin Endocrinol Metab* 2005 90: 6403-6409; September 20 2005.
- Pittman J et al. Antimetabolic Activity of 3,3',5'-triiodo-DL-thyronine in man. *Endocrinology*. Mar;64(3):466-468.
- Robin P, Peeters, Serge van der Geyten, Pieter J. Wouters, Veerle M. Darras, Hans van Toor, Ellen Kaptein, Theo J. Visser, and Greet Van den Bergh. Tissue Thyroid Hormone Levels in Critical Illness. *J Clin Endocrinol Metab* 2005 90: 6498-6507.
- Den Brinker et al. Euthyroid Sick Syndrome in Meningococcal Sepsis: The Impact of Peripheral Thyroid Hormone Metabolism and Binding Proteins. *The Journal of Clinical Endocrinology & Metabolism* 2005;90(10):5613-5620
- Peeters RP, Van der Geyten, Wouters PJ, Darras VM et al. Tissue Thyroid Hormone Levels in Critical Illness. *The Journal of Clinical Endocrinology & Metabolism* 2005;90(12):6498-6507
- Peeters RP, Wouters PJ, Kaptein E et al. Reduced Activation and Increased Inactivation of Thyroid Hormone in Tissues of Critically Ill Patients. *The Journal of Clinical Endocrinology & Metabolism* 2003;88(7):3202-3211
- Chopra I. A Study of Extrathyroidal conversion of thyroxine to T3 in vitro. *Endocrinology* 1977;101:53-64.
- Okamoto R, Leibfritz D. Adverse effects of reverse triiodothyronine on cellular metabolism as assessed by 1H and 3P NMR spectroscopy. *Res Exp Med* 1997;197(4):211-217.
- Larson FC, Albright EC. Inhibition of L-thyroxine Monodeiodination by Thyroxine Analogs. *J Clin Invest*. 1961 July; 40(7): 1132-1138.
- Pittman JA, Tingley JO, Nickerson JF, Hill SR. Antimetabolic activity of 3,3',5'-triiodo-DL-thyronine in man. *Metabolism* 1960;9:293-5.
- Roelen A et al. Association between Serum Interleukin-6 and Serum 3,5,3'-triiodo-L-thyronine in nonthyroidal illness. *JCEM* 1993;77(6):1695-1699.
- Hashimoto H et al. Their relationship between serum levels of interleukin-6 and thyroid hormone in children with acute respiratory infection. *JCEM* 1994;78(2):288-291.
- Yamazaki K et al. Interleukin-6 (IL-6) inhibits thyroid function in the presence of soluble IL-6 receptor in cultured human thyroid follicles. *Endocrinology* 1996;137(11):4857-4863.
- Baralena L et al. Relationship of the increased serum interleukin-6 concentration to changes of thyroid function in nonthyroidal illness. *J Endocrinol Invest* 1994;17:269-274.
- Yudkin JS et al. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction. *Atheroscler Thromb Vasc Biol* 1999;19:972-978.
- Henryk Zulewski, Beat Müller, Pascale Exer, André R. Miserez and Jean-Jacques Staub Estimation of Tissue Hypothyroidism by a New Clinical Score: Evaluation of Patients with Various Grades of Hypothyroidism and Controls. *The Journal of Clinical Endocrinology & Metabolism* 1997;82(3):771-776.
- Meier C, Tritschach P, Guglielmetti M, Staub J-J, Müller B. Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with overt primary thyroid failure: cross sectional survey. *British Med J* 2003;326:311-312
- Escobar-Morreale et al. Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. *J Clin Invest*, 1995
- De Giudice EM et al. Inadequate leptin level negatively affects body fat loss during a weight reduction program for childhood obesity. *Acta Paediatr* 2002;91:132-135.
- Naslund E et al. Associations of leptin, insulin resistance and thyroid function with long-term weight loss in dieting obese men. *J Internal Med* 2000;248:299-308.
- Fleisch AF, Agarwal N et al. Influences of Serum Leptin on Weight and Body Fat Growth in Children at High Risk for Adult Obesity. *J Endocrinology Metab* 2007;92(3):948-954



HOLTORF MEDICAL GROUP, INC.
www.HoltorfMed.com